|
|
|
Corporate Profile: Alethia Biotherapeutics
| Summary: |
Alethia Biotherapeutics is focused on the research and development of monoclonal antibodies for treatment of cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss.
|
| Address (HQ): |
141, Président-Kennedy Avenue
Suite SB-5100
Montréal, QC H2X 1Y4
Canada |
| Phone #'s (HQ): |
| Main |
(514) 858-7666 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax #'s (HQ): |
| Main |
(514) 858-5333 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Financial
information: |
| not known |
| Number
of employees: |
| not known |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
